CD274 and breast carcinoma: Further, cytotoxic agents other than PLK1 inhibitor have also been shown to increase PD-L1 expression, including paclitaxel in ovarian cancer26, CDK4/6 inhibitors48, and PARP inhibitors49 in breast cancer.